Central Trust Company’s Travere Therapeutics TVTX Stock Holding History

Central Trust Company’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-300	Closed	-$6K	–	1170
2015 Q4	$6K	Hold	300	–	–	﹤0.01%	1045
2015 Q3	$6K	Hold	300	–	–	﹤0.01%	1064
2015 Q2	$10K	Hold	300	–	–	﹤0.01%	1009
2015 Q1	$7K	Hold	300	–	–	﹤0.01%	1046
2014 Q4	$4K	Hold	300	–	–	﹤0.01%	1111
2014 Q3	$3K	Hold	300	–	–	﹤0.01%	1128
2014 Q2	$4K	Hold	300	–	–	﹤0.01%	1088
2014 Q1	$6K	Buy	+300	New	+$4.61K	﹤0.01%	1039

Other funds holding TVTX

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

LOAMU

Lombard Odier Asset Management (USA) New York $957M AUM 35.8% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Central Trust Company's TVTX Position: Q1 2016 in Review

Central Trust Company sold out of Travere Therapeutics (TVTX) in Q1 2016, closing a stake of 300 shares — an estimated $6K sold.

Central Trust Company first reported a position in TVTX in Q1 2014 and held it in 8 quarters. The position peaked at $10K in Q2 2015. 119 funds tracked by Wall St. Rank hold TVTX as of Q1 2016.

Central Trust Company reported no remaining Travere Therapeutics position as of Q1 2016 after selling out during the quarter.
Central Trust Company sold 300 Travere Therapeutics shares in Q1 2016, an estimated $6K.
Central Trust Company first reported a position in Travere Therapeutics in Q1 2014 and held it in 8 quarters.
Central Trust Company's Travere Therapeutics position peaked at $10K in Q2 2015.
119 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2016.

Based on Central Trust Company's 13F filing for Q1 2016, filed 11 Apr 2016.